<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694863</url>
  </required_header>
  <id_info>
    <org_study_id>2008.1</org_study_id>
    <secondary_id>ABR: NL22482.091.08</secondary_id>
    <secondary_id>CMO: 2008/77</secondary_id>
    <nct_id>NCT00694863</nct_id>
  </id_info>
  <brief_title>Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy</brief_title>
  <acronym>ACTHiMeN</acronym>
  <official_title>Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with long-acting synthetic
      adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous
      nephropathy and high for renal failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attainability of ACTH therapy with intramuscular injections twice a week for a period of 9 months, measured as the percentage of injections that has been received in line with the treatment schedule.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment with ACTH: number of remissions of proteinuria at the end of treatment</measure>
    <time_frame>9 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this open-label study all patients included are treated in the experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracosactide hexacetaat</intervention_name>
    <description>Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Synacthen Depot, long-acting synthetic ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven idiopathic membranous nephropathy.

          -  Nephrotic syndrome: proteinuria &gt; 3.5 g/day and serum albumine &lt; 30 g/l

          -  Normal or mildly impaired renal function (eGFR &gt; 60 ml/min, MDRD formula)

          -  High risk for renal failure: beta-2-microglobulin excretion &gt; 500 ng/min

          -  Relative contra-indication for cyclophosphamide treatment:

               -  fertility and wish for (future) family expanding

               -  high age ( &gt; 60 years)

               -  former cyclophosphamide treatment

               -  intolerance to cyclophosphamide

        Exclusion Criteria:

          -  Clinical,biochemical or histological signs of any underlying systemic disease

          -  Any infectious disease (including latent tuberculosis and/or latent amoebiasis)

          -  Active gastric or duodenal ulcers

          -  Pregnancy, lactation, inadequate contraceptives

          -  Clinical signs of renal vein thrombosis

          -  Asthma and /or any allergic conditions or hypersensitivity reactions

          -  Allergic reaction to synthetic ACTH in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack FM Wetzels, M.D.Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology, Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia M Hofstra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high risk for ESRD</keyword>
  <keyword>immunosuppressive treatment</keyword>
  <keyword>membranous nephropathy</keyword>
  <keyword>ACTH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
    <mesh_term>Adrenocorticotropin zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

